-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings / Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
Allogeneic
Salon B
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Evening Drinks Reception
Grand Foyer
-
iPSCs Technology
Salon A
Clinical grade iPSC line generation: which method is the ideal one ? As fully differentiated cells a
...
-
Autologous
Salon D
Developing robust processes in early phase with commercial already in mind Removing roadblocks to sc
...
-
Autologous
Salon D
The device used to manufacture an immunotherapeutic agent is a highly relevant factor in ensuring th
...
-
Allogeneic
Salon B
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Salon H
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings / Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Afternoon Refreshments
Grand Foyer
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Networking Lunch
Thomson Hall - First Floor
-
Measuring Product Potency
-
Measuring Product Potency
Salon C
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Registration
Grand Foyer
-
iPSCs Technology
Salon A
What are the manufacturing implications of the recent FDA guidelines from January 2024 on “Human Gen
...
-
Allogeneic
Salon B
What is the current terminal scale of allogeneic CGT production with respect to total cell numbers a
...
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings / Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Morning Refreshments
Grand Foyer
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
Allogeneic
Salon B
-
Measuring Product Potency
-
Measuring Product Potency
Salon C
-
iPSCs Technology
Salon A
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Salon H
)
The device used to manufacture an immunotherapeutic agent is a highly relevant factor in ensuring th ...)
)
![Sponsor Led Roundtable: De-risking programs and improving timelines when transitioning from pre-clinical to first in human and ultimately, commercial production [Allogeneic Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/WuXi-Advanced-Therapies.png/fit-in/500x9999/filters:no_upscale())
)
What are the manufacturing implications of the recent FDA guidelines from January 2024 on “Human Gen ...)
What is the current terminal scale of allogeneic CGT production with respect to total cell numbers a ...)
)
)
)
)
)
)
)
)
)
)
)
)
)